A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
ID Number 14-0715-01306Principal Investigator(s)
Jorge E Gomez
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to find out what effects, good and/or bad, one of the following treatments has on people with locally advanced, non-operable lung cancer with the specific gene alterations, EGFR mutation and/or ALK rearrangement.
Dr. Jorge Gomez
Recruiting Patients: Yes